Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
With
Northwestern University
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Age 18 - 55 years
2. Able to provide informed consent
3. Smoking history \< 10 pack-years
1. Methacholine PC20 \< 16 mg/ml or PD 20 \< 400 mcg/ml or albuterol response \> 12% on FEV1 after 4 puffs of albuterol
2. Currently prescribed ICS + LABA
3. Meet definition for Th2-low asthma: peripheral blood eosinophil count \< 300 and exhaled nitric oxide level \< 30 ppb.
You may not be if
1. History of allergy or intolerance to any medications used in this study
2. Medication exclusions:
1. Current use of medications that prolong QTc interval
2. Current use of omalizumab or other ant-IgE therapies
3. Current use of anti-IL 5 therapies
4. Current use of anticoagulants
3. Prednsione or other oral steroids within past 3 months
4. Pregnancy or lactation, or plans to become pregnant
5. Other respiratory or inflammatory disorders (e.g., sarcoidosis, emphysema)
6. Pre-existing liver disease by history
7. Smoking within the last 6 months
8. Exacerbation of asthma in past 3 months
9. Affected by a hearing disorder
10. Clinically significant medical condition (e.g., heart failure, seizure disorder) which may in-crease risk as determined by study investigator
11. Corrected QT interval \> 450 msec. Patients with known cardiac history or prolonged QT interval on a screening EKG are excluded given the small but real potential for macrolide-related side effects
Clareo Health | Azithromycin Treatment for the Airway Microbiome in Asthma
